nodes	percent_of_prediction	percent_of_DWPC	metapath
Bismuth Subsalicylate—PTGS2—glaucoma	0.621	1	CbGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—CNTF—glaucoma	0.0121	0.127	CbGpPWpGaD
Bismuth Subsalicylate—TF—Differentiation Pathway—NTF4—glaucoma	0.00636	0.0666	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—LMX1B—glaucoma	0.00401	0.042	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.00347	0.0363	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Prostaglandin Synthesis and Regulation—ANXA3—glaucoma	0.00275	0.0288	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.00237	0.0248	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Prostaglandin Synthesis and Regulation—PTGFR—glaucoma	0.00188	0.0197	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—TGFB2—glaucoma	0.00184	0.0193	CbGpPWpGaD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—TGFB2—glaucoma	0.00175	0.0183	CbGpPWpGaD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.00148	0.0154	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—HDAC9—glaucoma	0.00144	0.015	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—SOD1—glaucoma	0.00139	0.0146	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—PEX19—glaucoma	0.00135	0.0142	CbGpPWpGaD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—SOD1—glaucoma	0.00133	0.0139	CbGpPWpGaD
Bismuth Subsalicylate—ALB—HDL-mediated lipid transport—ABCA1—glaucoma	0.00109	0.0114	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.00103	0.0108	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet degranulation—FN1—glaucoma	0.000971	0.0102	CbGpPWpGaD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—FN1—glaucoma	0.000925	0.00968	CbGpPWpGaD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000915	0.00957	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Diclofenamide—glaucoma	0.000876	0.00309	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—FN1—glaucoma	0.00087	0.0091	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—MMP1—glaucoma	0.000868	0.00908	CbGpPWpGaD
Bismuth Subsalicylate—Erythema multiforme—Dorzolamide—glaucoma	0.000862	0.00304	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Pilocarpine—glaucoma	0.000861	0.00304	CcSEcCtD
Bismuth Subsalicylate—Asthma—Clonidine—glaucoma	0.000859	0.00303	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Carbachol—glaucoma	0.000855	0.00301	CcSEcCtD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CA1—glaucoma	0.000851	0.00891	CbGpPWpGaD
Bismuth Subsalicylate—Tinnitus—Dorzolamide—glaucoma	0.00085	0.00299	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Acetazolamide—glaucoma	0.000847	0.00299	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Levobunolol—glaucoma	0.000846	0.00298	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Travoprost—glaucoma	0.000846	0.00298	CcSEcCtD
Bismuth Subsalicylate—Pain—Latanoprost—glaucoma	0.000845	0.00298	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Methazolamide—glaucoma	0.000841	0.00296	CcSEcCtD
Bismuth Subsalicylate—TF—Differentiation Pathway—VEGFA—glaucoma	0.000836	0.00875	CbGpPWpGaD
Bismuth Subsalicylate—Tinnitus—Brinzolamide—glaucoma	0.000835	0.00294	CcSEcCtD
Bismuth Subsalicylate—Erythema—Brimonidine—glaucoma	0.000831	0.00293	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000816	0.00854	CbGpPWpGaD
Bismuth Subsalicylate—Dysgeusia—Brimonidine—glaucoma	0.000813	0.00287	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Methazolamide—glaucoma	0.000811	0.00286	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—glaucoma	0.000807	0.00844	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Methazolamide—glaucoma	0.000807	0.00284	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Metipranolol—glaucoma	0.000805	0.00284	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Pilocarpine—glaucoma	0.000803	0.00283	CcSEcCtD
Bismuth Subsalicylate—Erythema—Dorzolamide—glaucoma	0.000793	0.0028	CcSEcCtD
Bismuth Subsalicylate—Erythema—Travoprost—glaucoma	0.00079	0.00278	CcSEcCtD
Bismuth Subsalicylate—Oedema—Apraclonidine—glaucoma	0.00079	0.00278	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000787	0.00823	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Apraclonidine—glaucoma	0.000784	0.00277	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Diclofenamide—glaucoma	0.000784	0.00276	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Clonidine—glaucoma	0.000782	0.00276	CcSEcCtD
Bismuth Subsalicylate—Erythema—Brinzolamide—glaucoma	0.00078	0.00275	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Dorzolamide—glaucoma	0.000777	0.00274	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Travoprost—glaucoma	0.000773	0.00273	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—PITX2—glaucoma	0.000768	0.00804	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000768	0.00804	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Metipranolol—glaucoma	0.000767	0.0027	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Metipranolol—glaucoma	0.000766	0.0027	CcSEcCtD
Bismuth Subsalicylate—Drowsiness—Clonidine—glaucoma	0.000766	0.0027	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Brinzolamide—glaucoma	0.000764	0.00269	CcSEcCtD
Bismuth Subsalicylate—Headache—Metipranolol—glaucoma	0.000762	0.00269	CcSEcCtD
Bismuth Subsalicylate—Infection—Bimatoprost—glaucoma	0.00076	0.00268	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Levobunolol—glaucoma	0.000753	0.00266	CcSEcCtD
Bismuth Subsalicylate—Asthma—Betaxolol—glaucoma	0.000748	0.00264	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Carteolol—glaucoma	0.000745	0.00263	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Carbachol—glaucoma	0.00074	0.00261	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000737	0.00772	CbGpPWpGaD
Bismuth Subsalicylate—Dysgeusia—Pilocarpine—glaucoma	0.000734	0.00259	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Diclofenamide—glaucoma	0.000733	0.00258	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Levobunolol—glaucoma	0.000729	0.00257	CcSEcCtD
Bismuth Subsalicylate—Nausea—Metipranolol—glaucoma	0.000723	0.00255	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Clonidine—glaucoma	0.000722	0.00255	CcSEcCtD
Bismuth Subsalicylate—ALB—HDL-mediated lipid transport—APOE—glaucoma	0.000715	0.00749	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Carbachol—glaucoma	0.000715	0.00252	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Acetazolamide—glaucoma	0.000712	0.00251	CcSEcCtD
Bismuth Subsalicylate—Headache—Carteolol—glaucoma	0.000706	0.00249	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Diclofenamide—glaucoma	0.000705	0.00248	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Levobunolol—glaucoma	0.000704	0.00248	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Apraclonidine—glaucoma	0.000702	0.00247	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Latanoprost—glaucoma	0.000699	0.00246	CcSEcCtD
Bismuth Subsalicylate—Rash—Diclofenamide—glaucoma	0.000699	0.00246	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Methazolamide—glaucoma	0.000698	0.00246	CcSEcCtD
Bismuth Subsalicylate—Headache—Diclofenamide—glaucoma	0.000694	0.00245	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—FN1—glaucoma	0.00069	0.00722	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Carbachol—glaucoma	0.000688	0.00242	CcSEcCtD
Bismuth Subsalicylate—Hepatitis—Clonidine—glaucoma	0.000688	0.00242	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Clonidine—glaucoma	0.000684	0.00241	CcSEcCtD
Bismuth Subsalicylate—Rash—Carbachol—glaucoma	0.000682	0.0024	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—NGF—glaucoma	0.000682	0.00713	CbGpPWpGaD
Bismuth Subsalicylate—Dermatitis—Carbachol—glaucoma	0.000681	0.0024	CcSEcCtD
Bismuth Subsalicylate—Weight increased—Betaxolol—glaucoma	0.000681	0.0024	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Bimatoprost—glaucoma	0.000681	0.0024	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000678	0.0071	CbGpPWpGaD
Bismuth Subsalicylate—Oedema—Brimonidine—glaucoma	0.000678	0.00239	CcSEcCtD
Bismuth Subsalicylate—Headache—Carbachol—glaucoma	0.000678	0.00239	CcSEcCtD
Bismuth Subsalicylate—Pain—Apraclonidine—glaucoma	0.000675	0.00238	CcSEcCtD
Bismuth Subsalicylate—Constipation—Apraclonidine—glaucoma	0.000675	0.00238	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Bimatoprost—glaucoma	0.000674	0.00238	CcSEcCtD
Bismuth Subsalicylate—Infection—Brimonidine—glaucoma	0.000673	0.00237	CcSEcCtD
Bismuth Subsalicylate—Nausea—Carteolol—glaucoma	0.000669	0.00236	CcSEcCtD
Bismuth Subsalicylate—Headache—Levobunolol—glaucoma	0.000667	0.00235	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—TXN—glaucoma	0.000666	0.00697	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Diclofenamide—glaucoma	0.000658	0.00232	CcSEcCtD
Bismuth Subsalicylate—Pain—Bimatoprost—glaucoma	0.000655	0.00231	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Latanoprost—glaucoma	0.000653	0.0023	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Dorzolamide—glaucoma	0.000653	0.0023	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Apraclonidine—glaucoma	0.000651	0.00229	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Methazolamide—glaucoma	0.000649	0.00229	CcSEcCtD
Bismuth Subsalicylate—TF—HIF-1-alpha transcription factor network—VEGFA—glaucoma	0.000648	0.00678	CbGpPWpGaD
Bismuth Subsalicylate—Oedema—Dorzolamide—glaucoma	0.000647	0.00228	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000646	0.00677	CbGpPWpGaD
Bismuth Subsalicylate—Abdominal pain upper—Timolol—glaucoma	0.000646	0.00228	CcSEcCtD
Bismuth Subsalicylate—Oedema—Travoprost—glaucoma	0.000645	0.00227	CcSEcCtD
Bismuth Subsalicylate—Rash—Methazolamide—glaucoma	0.000643	0.00227	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Methazolamide—glaucoma	0.000643	0.00227	CcSEcCtD
Bismuth Subsalicylate—Nausea—Carbachol—glaucoma	0.000642	0.00226	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Clonidine—glaucoma	0.000641	0.00226	CcSEcCtD
Bismuth Subsalicylate—Infection—Travoprost—glaucoma	0.00064	0.00226	CcSEcCtD
Bismuth Subsalicylate—Headache—Methazolamide—glaucoma	0.000639	0.00225	CcSEcCtD
Bismuth Subsalicylate—Nausea—Levobunolol—glaucoma	0.000633	0.00223	CcSEcCtD
Bismuth Subsalicylate—Infection—Brinzolamide—glaucoma	0.000632	0.00223	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—PTGS2—glaucoma	0.000632	0.00661	CbGpPWpGaD
Bismuth Subsalicylate—Epistaxis—Betaxolol—glaucoma	0.000629	0.00222	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Acetazolamide—glaucoma	0.000628	0.00221	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipoprotein metabolism—ABCA1—glaucoma	0.000625	0.00654	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Prostaglandin Synthesis and Regulation—EDN1—glaucoma	0.000625	0.00654	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Latanoprost—glaucoma	0.000623	0.0022	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Latanoprost—glaucoma	0.000622	0.00219	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Acetazolamide—glaucoma	0.000622	0.00219	CcSEcCtD
Bismuth Subsalicylate—Headache—Latanoprost—glaucoma	0.000619	0.00218	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.000619	0.00647	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Dorzolamide—glaucoma	0.000617	0.00218	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Pilocarpine—glaucoma	0.000617	0.00217	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Acetazolamide—glaucoma	0.000614	0.00216	CcSEcCtD
Bismuth Subsalicylate—Oedema—Pilocarpine—glaucoma	0.000612	0.00216	CcSEcCtD
Bismuth Subsalicylate—Asthma—Timolol—glaucoma	0.000611	0.00215	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.00061	0.00639	CbGpPWpGaD
Bismuth Subsalicylate—Infection—Pilocarpine—glaucoma	0.000608	0.00214	CcSEcCtD
Bismuth Subsalicylate—Nausea—Methazolamide—glaucoma	0.000606	0.00214	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Brimonidine—glaucoma	0.000603	0.00212	CcSEcCtD
Bismuth Subsalicylate—Erythema—Clonidine—glaucoma	0.000599	0.00211	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Brimonidine—glaucoma	0.000597	0.0021	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Betaxolol—glaucoma	0.000596	0.0021	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Pilocarpine—glaucoma	0.000583	0.00206	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Acetazolamide—glaucoma	0.000582	0.00205	CcSEcCtD
Bismuth Subsalicylate—Pain—Brimonidine—glaucoma	0.00058	0.00204	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Dorzolamide—glaucoma	0.000575	0.00203	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Dorzolamide—glaucoma	0.00057	0.00201	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Travoprost—glaucoma	0.000567	0.002	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Brinzolamide—glaucoma	0.000566	0.00199	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Dorzolamide—glaucoma	0.000563	0.00198	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Acetazolamide—glaucoma	0.000561	0.00198	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Brinzolamide—glaucoma	0.00056	0.00197	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Apraclonidine—glaucoma	0.000559	0.00197	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Acetazolamide—glaucoma	0.000558	0.00197	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Betaxolol—glaucoma	0.000558	0.00197	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet degranulation—VEGFA—glaucoma	0.000555	0.00581	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Dorzolamide—glaucoma	0.000554	0.00195	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Brinzolamide—glaucoma	0.000553	0.00195	CcSEcCtD
Bismuth Subsalicylate—Pain—Travoprost—glaucoma	0.000551	0.00194	CcSEcCtD
Bismuth Subsalicylate—Constipation—Travoprost—glaucoma	0.000551	0.00194	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.000549	0.00574	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Brinzolamide—glaucoma	0.000544	0.00192	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Pilocarpine—glaucoma	0.000544	0.00192	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Bimatoprost—glaucoma	0.000542	0.00191	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Apraclonidine—glaucoma	0.00054	0.0019	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Pilocarpine—glaucoma	0.000538	0.0019	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Dorzolamide—glaucoma	0.000533	0.00188	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Pilocarpine—glaucoma	0.000532	0.00187	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Travoprost—glaucoma	0.000531	0.00187	CcSEcCtD
Bismuth Subsalicylate—TF—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	0.000529	0.00554	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TXN—glaucoma	0.000528	0.00553	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Brinzolamide—glaucoma	0.000524	0.00185	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Eicosanoid Synthesis—PTGS2—glaucoma	0.000524	0.00549	CbGpPWpGaD
Bismuth Subsalicylate—Pain—Pilocarpine—glaucoma	0.000523	0.00184	CcSEcCtD
Bismuth Subsalicylate—Constipation—Pilocarpine—glaucoma	0.000523	0.00184	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Apraclonidine—glaucoma	0.000522	0.00184	CcSEcCtD
Bismuth Subsalicylate—Erythema—Betaxolol—glaucoma	0.000521	0.00184	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Dorzolamide—glaucoma	0.000514	0.00181	CcSEcCtD
Bismuth Subsalicylate—Epistaxis—Timolol—glaucoma	0.000514	0.00181	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000513	0.00537	CbGpPWpGaD
Bismuth Subsalicylate—Body temperature increased—Dorzolamide—glaucoma	0.000512	0.0018	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Betaxolol—glaucoma	0.00051	0.0018	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Bimatoprost—glaucoma	0.000506	0.00178	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Brinzolamide—glaucoma	0.000506	0.00178	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Pilocarpine—glaucoma	0.000504	0.00178	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Apraclonidine—glaucoma	0.000502	0.00177	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Apraclonidine—glaucoma	0.000497	0.00175	CcSEcCtD
Bismuth Subsalicylate—Headache—Apraclonidine—glaucoma	0.000495	0.00174	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Clonidine—glaucoma	0.000493	0.00174	CcSEcCtD
Bismuth Subsalicylate—Oedema—Clonidine—glaucoma	0.000488	0.00172	CcSEcCtD
Bismuth Subsalicylate—Hallucination—Timolol—glaucoma	0.000487	0.00172	CcSEcCtD
Bismuth Subsalicylate—Infection—Clonidine—glaucoma	0.000485	0.00171	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Pilocarpine—glaucoma	0.000484	0.0017	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Acetazolamide—glaucoma	0.000483	0.0017	CcSEcCtD
Bismuth Subsalicylate—Rash—Bimatoprost—glaucoma	0.000483	0.0017	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Bimatoprost—glaucoma	0.000482	0.0017	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Brimonidine—glaucoma	0.00048	0.00169	CcSEcCtD
Bismuth Subsalicylate—Headache—Bimatoprost—glaucoma	0.00048	0.00169	CcSEcCtD
Bismuth Subsalicylate—Nausea—Apraclonidine—glaucoma	0.000469	0.00165	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—C1QB—glaucoma	0.000469	0.00491	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Acetazolamide—glaucoma	0.000467	0.00165	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Clonidine—glaucoma	0.000466	0.00164	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Dorzolamide—glaucoma	0.000458	0.00161	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Travoprost—glaucoma	0.000456	0.00161	CcSEcCtD
Bismuth Subsalicylate—Tinnitus—Timolol—glaucoma	0.000456	0.00161	CcSEcCtD
Bismuth Subsalicylate—Nausea—Bimatoprost—glaucoma	0.000455	0.0016	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.000453	0.00474	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	0.000453	0.00474	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Brinzolamide—glaucoma	0.00045	0.00159	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Acetazolamide—glaucoma	0.000449	0.00158	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Brimonidine—glaucoma	0.000448	0.00158	CcSEcCtD
Bismuth Subsalicylate—TF—Transmembrane transport of small molecules—SLC6A1—glaucoma	0.000447	0.00468	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Dorzolamide—glaucoma	0.000443	0.00156	CcSEcCtD
Bismuth Subsalicylate—Headache—Acetazolamide—glaucoma	0.000442	0.00156	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Travoprost—glaucoma	0.000441	0.00155	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—glaucoma	0.000438	0.00459	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Brinzolamide—glaucoma	0.000435	0.00154	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Clonidine—glaucoma	0.000434	0.00153	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Pilocarpine—glaucoma	0.000433	0.00153	CcSEcCtD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—FN1—glaucoma	0.00043	0.00451	CbGpPWpGaD
Bismuth Subsalicylate—Confusional state—Betaxolol—glaucoma	0.000429	0.00151	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Dorzolamide—glaucoma	0.000428	0.00151	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TXN—glaucoma	0.000428	0.00447	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Brimonidine—glaucoma	0.000427	0.00151	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Brimonidine—glaucoma	0.000427	0.00151	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Overview of nanoparticle effects—TNF—glaucoma	0.000427	0.00446	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Travoprost—glaucoma	0.000426	0.0015	CcSEcCtD
Bismuth Subsalicylate—Erythema—Timolol—glaucoma	0.000426	0.0015	CcSEcCtD
Bismuth Subsalicylate—Oedema—Betaxolol—glaucoma	0.000425	0.0015	CcSEcCtD
Bismuth Subsalicylate—Headache—Brimonidine—glaucoma	0.000425	0.0015	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Clonidine—glaucoma	0.000425	0.0015	CcSEcCtD
Bismuth Subsalicylate—Infection—Betaxolol—glaucoma	0.000422	0.00149	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Brinzolamide—glaucoma	0.000421	0.00148	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—TGFB2—glaucoma	0.000421	0.0044	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Acetazolamide—glaucoma	0.000419	0.00148	CcSEcCtD
Bismuth Subsalicylate—Diarrhoea—Pilocarpine—glaucoma	0.000419	0.00148	CcSEcCtD
Bismuth Subsalicylate—Constipation—Clonidine—glaucoma	0.000418	0.00147	CcSEcCtD
Bismuth Subsalicylate—Pain—Clonidine—glaucoma	0.000418	0.00147	CcSEcCtD
Bismuth Subsalicylate—Dysgeusia—Timolol—glaucoma	0.000417	0.00147	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipid and lipoprotein metabolism—ABCA1—glaucoma	0.000415	0.00435	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Dorzolamide—glaucoma	0.000412	0.00145	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—ABCA1—glaucoma	0.000411	0.0043	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Lipoprotein metabolism—APOE—glaucoma	0.000411	0.0043	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—ABCA1—glaucoma	0.000409	0.00428	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Dorzolamide—glaucoma	0.000408	0.00144	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Dorzolamide—glaucoma	0.000408	0.00144	CcSEcCtD
Bismuth Subsalicylate—Rash—Travoprost—glaucoma	0.000406	0.00143	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Travoprost—glaucoma	0.000406	0.00143	CcSEcCtD
Bismuth Subsalicylate—Headache—Dorzolamide—glaucoma	0.000406	0.00143	CcSEcCtD
Bismuth Subsalicylate—Anorexia—Betaxolol—glaucoma	0.000405	0.00143	CcSEcCtD
Bismuth Subsalicylate—Vomiting—Brinzolamide—glaucoma	0.000405	0.00143	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Pilocarpine—glaucoma	0.000404	0.00143	CcSEcCtD
Bismuth Subsalicylate—Headache—Travoprost—glaucoma	0.000404	0.00142	CcSEcCtD
Bismuth Subsalicylate—Nausea—Brimonidine—glaucoma	0.000403	0.00142	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Clonidine—glaucoma	0.000403	0.00142	CcSEcCtD
Bismuth Subsalicylate—Rash—Brinzolamide—glaucoma	0.000401	0.00141	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Brinzolamide—glaucoma	0.000401	0.00141	CcSEcCtD
Bismuth Subsalicylate—Headache—Brinzolamide—glaucoma	0.000399	0.00141	CcSEcCtD
Bismuth Subsalicylate—PTGS2—S1P1 pathway—VEGFA—glaucoma	0.000395	0.00413	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Pilocarpine—glaucoma	0.000389	0.00137	CcSEcCtD
Bismuth Subsalicylate—Urticaria—Clonidine—glaucoma	0.000388	0.00137	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Clonidine—glaucoma	0.000386	0.00136	CcSEcCtD
Bismuth Subsalicylate—Rash—Pilocarpine—glaucoma	0.000386	0.00136	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Pilocarpine—glaucoma	0.000385	0.00136	CcSEcCtD
Bismuth Subsalicylate—Nausea—Dorzolamide—glaucoma	0.000385	0.00136	CcSEcCtD
Bismuth Subsalicylate—Headache—Pilocarpine—glaucoma	0.000383	0.00135	CcSEcCtD
Bismuth Subsalicylate—Nausea—Travoprost—glaucoma	0.000383	0.00135	CcSEcCtD
Bismuth Subsalicylate—Nausea—Brinzolamide—glaucoma	0.000378	0.00133	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Betaxolol—glaucoma	0.000374	0.00132	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Betaxolol—glaucoma	0.00037	0.0013	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—SOD1—glaucoma	0.000367	0.00384	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—SOD1—glaucoma	0.000364	0.00381	CbGpPWpGaD
Bismuth Subsalicylate—Constipation—Betaxolol—glaucoma	0.000364	0.00128	CcSEcCtD
Bismuth Subsalicylate—Pain—Betaxolol—glaucoma	0.000364	0.00128	CcSEcCtD
Bismuth Subsalicylate—Nausea—Pilocarpine—glaucoma	0.000363	0.00128	CcSEcCtD
Bismuth Subsalicylate—Feeling abnormal—Betaxolol—glaucoma	0.00035	0.00124	CcSEcCtD
Bismuth Subsalicylate—Confusional state—Timolol—glaucoma	0.00035	0.00123	CcSEcCtD
Bismuth Subsalicylate—Oedema—Timolol—glaucoma	0.000347	0.00122	CcSEcCtD
Bismuth Subsalicylate—Pruritus—Clonidine—glaucoma	0.000346	0.00122	CcSEcCtD
Bismuth Subsalicylate—Infection—Timolol—glaucoma	0.000345	0.00122	CcSEcCtD
Bismuth Subsalicylate—ALB—FOXA2 and FOXA3 transcription factor networks—NR3C1—glaucoma	0.00034	0.00356	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Overview of nanoparticle effects—TNF—glaucoma	0.000339	0.00354	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Betaxolol—glaucoma	0.000338	0.00119	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Betaxolol—glaucoma	0.000336	0.00119	CcSEcCtD
Bismuth Subsalicylate—ALB—Platelet degranulation—TGFB2—glaucoma	0.000335	0.00351	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Clonidine—glaucoma	0.000334	0.00118	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—ABCA1—glaucoma	0.000332	0.00348	CbGpPWpGaD
Bismuth Subsalicylate—Anorexia—Timolol—glaucoma	0.000331	0.00117	CcSEcCtD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC4A4—glaucoma	0.000328	0.00343	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—ABCA1—glaucoma	0.000326	0.00342	CbGpPWpGaD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—VEGFA—glaucoma	0.000326	0.00341	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Clonidine—glaucoma	0.000323	0.00114	CcSEcCtD
Bismuth Subsalicylate—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—glaucoma	0.00032	0.00335	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—TGFB2—glaucoma	0.000319	0.00334	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—SOD1—glaucoma	0.000319	0.00334	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Clonidine—glaucoma	0.000311	0.00109	CcSEcCtD
Bismuth Subsalicylate—Somnolence—Timolol—glaucoma	0.000309	0.00109	CcSEcCtD
Bismuth Subsalicylate—Rash—Clonidine—glaucoma	0.000308	0.00109	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Clonidine—glaucoma	0.000308	0.00108	CcSEcCtD
Bismuth Subsalicylate—Headache—Clonidine—glaucoma	0.000306	0.00108	CcSEcCtD
Bismuth Subsalicylate—Dyspepsia—Timolol—glaucoma	0.000306	0.00108	CcSEcCtD
Bismuth Subsalicylate—Decreased appetite—Timolol—glaucoma	0.000302	0.00106	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTT1—glaucoma	0.000302	0.00316	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Betaxolol—glaucoma	0.000301	0.00106	CcSEcCtD
Bismuth Subsalicylate—Pain—Timolol—glaucoma	0.000297	0.00105	CcSEcCtD
Bismuth Subsalicylate—ALB—Folate Metabolism—SOD1—glaucoma	0.000296	0.0031	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Arachidonic acid metabolism—PTGS2—glaucoma	0.000291	0.00305	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—SOD1—glaucoma	0.000291	0.00305	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Betaxolol—glaucoma	0.000291	0.00103	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—MTHFR—glaucoma	0.000291	0.00304	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Clonidine—glaucoma	0.00029	0.00102	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—MTHFR—glaucoma	0.000289	0.00302	CbGpPWpGaD
Bismuth Subsalicylate—Feeling abnormal—Timolol—glaucoma	0.000286	0.00101	CcSEcCtD
Bismuth Subsalicylate—Dizziness—Betaxolol—glaucoma	0.000281	0.000991	CcSEcCtD
Bismuth Subsalicylate—TF—SIDS Susceptibility Pathways—TNF—glaucoma	0.000279	0.00292	CbGpPWpGaD
Bismuth Subsalicylate—Urticaria—Timolol—glaucoma	0.000276	0.000973	CcSEcCtD
Bismuth Subsalicylate—Body temperature increased—Timolol—glaucoma	0.000275	0.000968	CcSEcCtD
Bismuth Subsalicylate—ALB—Lipid and lipoprotein metabolism—APOE—glaucoma	0.000273	0.00286	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—GSTM1—glaucoma	0.000271	0.00284	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Lipid and lipoprotein metabolism—CAV1—glaucoma	0.000271	0.00283	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Betaxolol—glaucoma	0.00027	0.000953	CcSEcCtD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—APOE—glaucoma	0.000269	0.00281	CbGpPWpGaD
Bismuth Subsalicylate—Rash—Betaxolol—glaucoma	0.000268	0.000945	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Betaxolol—glaucoma	0.000268	0.000944	CcSEcCtD
Bismuth Subsalicylate—Headache—Betaxolol—glaucoma	0.000266	0.000939	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—ABCA1—glaucoma	0.000264	0.00276	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—SOD1—glaucoma	0.000254	0.00266	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Betaxolol—glaucoma	0.000253	0.00089	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—NGFR—glaucoma	0.000249	0.0026	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—PEX19—glaucoma	0.000247	0.00258	CbGpPWpGaD
Bismuth Subsalicylate—TF—Platelet activation, signaling and aggregation—VEGFA—glaucoma	0.000246	0.00258	CbGpPWpGaD
Bismuth Subsalicylate—Pruritus—Timolol—glaucoma	0.000246	0.000866	CcSEcCtD
Bismuth Subsalicylate—TF—Hemostasis—MMP1—glaucoma	0.000243	0.00254	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—SOD1—glaucoma	0.000242	0.00253	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—CYP1B1—glaucoma	0.000241	0.00252	CbGpPWpGaD
Bismuth Subsalicylate—Diarrhoea—Timolol—glaucoma	0.000238	0.000838	CcSEcCtD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—SOD1—glaucoma	0.000235	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—MTHFR—glaucoma	0.000235	0.00246	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000234	0.00245	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—CAV1—glaucoma	0.000233	0.00244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.000233	0.00244	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—MTHFR—glaucoma	0.000231	0.00241	CbGpPWpGaD
Bismuth Subsalicylate—Dizziness—Timolol—glaucoma	0.00023	0.00081	CcSEcCtD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000225	0.00235	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—FN1—glaucoma	0.000222	0.00232	CbGpPWpGaD
Bismuth Subsalicylate—Vomiting—Timolol—glaucoma	0.000221	0.000779	CcSEcCtD
Bismuth Subsalicylate—Rash—Timolol—glaucoma	0.000219	0.000772	CcSEcCtD
Bismuth Subsalicylate—Dermatitis—Timolol—glaucoma	0.000219	0.000772	CcSEcCtD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC6A13—glaucoma	0.000219	0.00229	CbGpPWpGaD
Bismuth Subsalicylate—Headache—Timolol—glaucoma	0.000218	0.000767	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—BDNF—glaucoma	0.000216	0.00226	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000215	0.00225	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NARFL—glaucoma	0.000212	0.00221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA5A—glaucoma	0.000212	0.00221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—IL1A—glaucoma	0.000208	0.00217	CbGpPWpGaD
Bismuth Subsalicylate—Nausea—Timolol—glaucoma	0.000206	0.000727	CcSEcCtD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	0.000195	0.00204	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Biological oxidations—GSTM1—glaucoma	0.000192	0.00201	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—MTHFR—glaucoma	0.000187	0.00195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—PTGS2—glaucoma	0.000185	0.00194	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	0.000183	0.00192	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000178	0.00187	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—FN1—glaucoma	0.000177	0.00185	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—NOS3—glaucoma	0.000176	0.00184	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—FN1—glaucoma	0.000168	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NARFL—glaucoma	0.000168	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA5A—glaucoma	0.000168	0.00176	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Aryl Hydrocarbon Receptor—TNF—glaucoma	0.000167	0.00175	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC4A4—glaucoma	0.000167	0.00174	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN2A—glaucoma	0.000163	0.00171	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000161	0.00168	CbGpPWpGaD
Bismuth Subsalicylate—ALB—SLC-mediated transmembrane transport—SLC6A1—glaucoma	0.00016	0.00168	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—glaucoma	0.000156	0.00163	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—LRP12—glaucoma	0.000152	0.00159	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—TGFB2—glaucoma	0.000149	0.00156	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000148	0.00155	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000147	0.00154	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—C-MYB transcription factor network—CDKN1B—glaucoma	0.000145	0.00151	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CTSA—glaucoma	0.000144	0.00151	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA5A—glaucoma	0.000136	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NARFL—glaucoma	0.000136	0.00142	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—VEGFA—glaucoma	0.000127	0.00133	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	0.000126	0.00132	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Selenium Micronutrient Network—TNF—glaucoma	0.000125	0.00131	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Vitamin B12 Metabolism—TNF—glaucoma	0.000124	0.0013	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—PTGS2—glaucoma	0.000119	0.00125	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—SOD1—glaucoma	0.000113	0.00118	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC6A13—glaucoma	0.000111	0.00116	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—CDKN1B—glaucoma	0.00011	0.00115	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	0.000108	0.00113	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA1—glaucoma	0.000103	0.00108	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—MMP9—glaucoma	0.000102	0.00107	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet degranulation—VEGFA—glaucoma	0.000101	0.00106	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TNF—glaucoma	0.000101	0.00106	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CTSA—glaucoma	0.0001	0.00105	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	9.93e-05	0.00104	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HEYL—glaucoma	9.8e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—FGFR1OP—glaucoma	9.8e-05	0.00103	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—glaucoma	9.64e-05	0.00101	CbGpPWpGaD
Bismuth Subsalicylate—TF—Hemostasis—TP53—glaucoma	9.6e-05	0.001	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CA2—glaucoma	9.45e-05	0.000989	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	9.24e-05	0.000967	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	9.24e-05	0.000967	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Folate Metabolism—TP53—glaucoma	8.92e-05	0.000933	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA1—glaucoma	8.2e-05	0.000859	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Transmembrane transport of small molecules—SLC6A1—glaucoma	8.14e-05	0.000852	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Selenium Micronutrient Network—TNF—glaucoma	8.04e-05	0.000841	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CTSA—glaucoma	7.95e-05	0.000832	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TNF—glaucoma	7.86e-05	0.000822	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—FN1—glaucoma	7.84e-05	0.000821	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TGFB2—glaucoma	7.67e-05	0.000802	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CA2—glaucoma	7.5e-05	0.000785	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	7.5e-05	0.000785	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	7.33e-05	0.000768	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	7.33e-05	0.000768	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Spinal Cord Injury—TP53—glaucoma	6.93e-05	0.000725	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—TXN—glaucoma	6.66e-05	0.000697	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA1—glaucoma	6.64e-05	0.000695	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CTSA—glaucoma	6.43e-05	0.000673	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	6.24e-05	0.000653	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—HDAC9—glaucoma	6.11e-05	0.00064	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—APOE—glaucoma	6.08e-05	0.000636	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CA2—glaucoma	6.07e-05	0.000635	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—CAV1—glaucoma	6.02e-05	0.00063	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	5.93e-05	0.000621	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	5.93e-05	0.000621	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—SOD1—glaucoma	5.81e-05	0.000608	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	5.34e-05	0.000559	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—TXN—glaucoma	5.29e-05	0.000553	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTT1—glaucoma	5.16e-05	0.00054	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	4.82e-05	0.000505	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	4.78e-05	0.0005	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	4.71e-05	0.000493	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Platelet activation, signaling and aggregation—VEGFA—glaucoma	4.49e-05	0.00047	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—MMP1—glaucoma	4.43e-05	0.000464	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—TXN—glaucoma	4.28e-05	0.000448	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—CAV1—glaucoma	4.25e-05	0.000445	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	4.16e-05	0.000436	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—ABCA1—glaucoma	4.11e-05	0.000431	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CYP1B1—glaucoma	4.11e-05	0.000431	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTT1—glaucoma	4.1e-05	0.000429	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—FN1—glaucoma	4.04e-05	0.000423	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—APOE—glaucoma	3.9e-05	0.000408	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—CAV1—glaucoma	3.87e-05	0.000405	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTT1—glaucoma	3.32e-05	0.000347	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—GSTM1—glaucoma	3.29e-05	0.000344	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN2B—glaucoma	3.29e-05	0.000344	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CYP1B1—glaucoma	3.27e-05	0.000342	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—ABCA1—glaucoma	3.27e-05	0.000342	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—NOS3—glaucoma	3.21e-05	0.000336	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—MTHFR—glaucoma	2.91e-05	0.000304	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—MTHFR—glaucoma	2.76e-05	0.000288	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—APOE—glaucoma	2.71e-05	0.000283	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—CAV1—glaucoma	2.68e-05	0.000281	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	2.67e-05	0.00028	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CYP1B1—glaucoma	2.64e-05	0.000277	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—ABCA1—glaucoma	2.64e-05	0.000277	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—GSTM1—glaucoma	2.61e-05	0.000273	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—APOE—glaucoma	2.57e-05	0.000268	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CAV1—glaucoma	2.54e-05	0.000266	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—BAD—glaucoma	2.39e-05	0.00025	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—VEGFA—glaucoma	2.31e-05	0.000242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—MTHFR—glaucoma	2.31e-05	0.000242	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—APOE—glaucoma	2.15e-05	0.000225	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—CAV1—glaucoma	2.13e-05	0.000223	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—GSTM1—glaucoma	2.11e-05	0.000221	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—NOS3—glaucoma	2.03e-05	0.000212	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—NOS3—glaucoma	1.92e-05	0.000201	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—MTHFR—glaucoma	1.87e-05	0.000195	CbGpPWpGaD
Bismuth Subsalicylate—PTGS1—Metabolism—PTGS2—glaucoma	1.85e-05	0.000194	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Hemostasis—TP53—glaucoma	1.75e-05	0.000183	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—APOE—glaucoma	1.74e-05	0.000182	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—CAV1—glaucoma	1.72e-05	0.00018	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Disease—CDKN1B—glaucoma	1.66e-05	0.000174	CbGpPWpGaD
Bismuth Subsalicylate—PTGS2—Metabolism—NOS3—glaucoma	1.61e-05	0.000168	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—NOS3—glaucoma	1.3e-05	0.000136	CbGpPWpGaD
Bismuth Subsalicylate—ALB—Metabolism—PTGS2—glaucoma	1.19e-05	0.000125	CbGpPWpGaD
